LISTING OF CLAIMS

1. (Original) A compound of formula (I)



(I)

or a pharmaceutically acceptable salt, solvate or derivative thereof.

2. (Original) A pharmaceutical composition comprising the compound according to claim 1 and one or more pharmaceutically acceptable excipients, diluents or carriers.

3. (Cancelled).

4. (Cancelled).

5. (Original) A compound according to claim 1 for use as a reverse transcriptase inhibitor or modulator.

6. (Original) A composition according to claim 2 for use as a reverse transcriptase inhibitor or modulator.

7. (Original) A compound according to claim 1 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

8. (Original) A composition according to claim 2 for use in the treatment of an HIV or genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS).

9. (Withdrawn) A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a compound according to claim 1.

10. (Withdrawn) A method of treating an HIV or a genetically-related retroviral infection, or a resulting acquired immune deficiency syndrome (AIDS), comprising administering an effective amount of a composition according to claim 2.

11. (Withdrawn) A process for preparing the compound of formula (I)



(I)

or a salt, solvate or pharmaceutically acceptable derivative thereof, which comprises:

(A) condensing a compound of formulae (II), (VI) or (VII)



(II)



(VI)



(VII)

wherein L^1 and L^2 are leaving groups;

with the compound of formula (V)

$H_2NNHCH_2CH_2OH$ (V)

or a salt or hydrate thereof;

(B) alkylating the pyrazole of formula (XIII)



(XIII)

with an alkylating agent of formula (XIV)

Lg-CH_2CH_2OH (XIV)

or a protected derivative thereof;

(C) deprotecting a protected derivative of the compound of formula (I);

and optionally converting the compound of formula (I) prepared by any one of steps (A) to (C) into a pharmaceutically acceptable salt, solvate or derivative thereof.

12. (Withdrawn) A process according to claim 11 wherein L^1 and L^2 are each independently selected from $-N(C_1-C_6\ alkyl)_2$ and $-N(CH_3)_2$.

13. (Withdrawn) A compound of formula (II)



(II)

14. (Withdrawn) A compound of formula (VI)



(VI)

wherein L^1 is a leaving group.

15. (Withdrawn) A compound of formula (VII)



(VII)

wherein L^2 is a leaving group.

16. (Withdrawn) A compund according to claim 14 or 15 wherein L^1 and L^2 are each independently selected from $-N(C_1-C_6\ alkyl)_2$ and $-N(CH_3)_2$.

17. (Withdrawn) A compound of formula (VIII)



(VIII)

18. (Withdrawn) A compound of formula (IX)



(IX).

19. (Original) A compound of formula (XIII)



(XIII)